Zoetis Inc. (ZTS)

Market Cap	54.78B -29.4%
Revenue (ttm)	9.47B +2.3%
Net Income	2.67B +7.5%
EPS	6.02 +10.1%
Shares Out	422.13M
PE Ratio	21.55
Forward PE	18.49
Dividend	$2.12 (1.63%)
Ex-Dividend Date	Apr 20, 2026

Volume	3,617,258
Open	129.10
Previous Close	128.95
Day's Range	128.44 - 131.34
52-Week Range	115.25 - 177.00
Beta	0.96
Analysts	Buy
Price Target	156.20 (+20.38%)
Earnings Date	Feb 12, 2026

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 14,500
• Stock Exchange: NYSE
• Ticker Symbol: ZTS
• Website: https://www.zoetis.com

Financial Performance

In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.

Analyst Summary

According to 11 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $156.2, which is an increase of 20.38% from the latest price.

Price Target

$156.2

(20.38% upside)

Analyst Consensus: Buy